Ashvattha Therapeutics, a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target and reprogram activated cells in regions of inflammation, announced additional financing as an extension of its Series B of up to $50 million led by Tribe Capital with existing investors led by Natural Capital. The funding will enable Ashvattha to complete the ongoing Phase 2 ophthalmology trial and Phase 1/2 neuroinflammation trial.